Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 357.5 JPY 2.48% Market Closed
Market Cap: ¥556.8B

P/FCFE

16.3
Current
43%
Cheaper
vs 3-y average of 28.6

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
16.3
=
Market Cap
¥537.2B
/
Free Cash Flow to Equity
¥32.6B

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
16.3
=
Market Cap
¥537.2B
/
Free Cash Flow to Equity
¥32.6B

Valuation Scenarios

Rohto Pharmaceutical Co Ltd is trading below its 3-year average

If P/FCFE returns to its 3-Year Average (28.6), the stock would be worth ¥4 126.42 (75% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+97%
Average Upside
60%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 16.3 ¥2 357.5
0%
3-Year Average 28.6 ¥4 126.42
+75%
5-Year Average 32.1 ¥4 634.42
+97%
Industry Average 21.7 ¥3 130.14
+33%
Country Average 22.4 ¥3 228.36
+37%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
JP
Rohto Pharmaceutical Co Ltd
TSE:4527
532.7B JPY 16.3 15.5
FR
L'Oreal SA
PAR:OR
195.4B EUR 19.8 31.9
UK
Unilever PLC
LSE:ULVR
96.1B GBP 16.8 11.7
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
5.3T INR 58.8 35.2
UK
HALEON PLC
LSE:HLN
30.6B GBP 53.2 18.4
US
Estee Lauder Companies Inc
NYSE:EL
28.7B USD 21.2 -161.1
DE
Beiersdorf AG
XETRA:BEI
15.5B EUR 67.1 16.5
JP
Kao Corp
TSE:4452
2.7T JPY 25.2 22.1
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
1.1T INR 73.1 59.9
CA
Relevium Technologies Inc
XTSX:RLV
12.2B CAD 603 -4 624.4
IN
Dabur India Ltd
NSE:DABUR
783.1B INR 69.8 42.5
P/E Multiple
Earnings Growth PEG
JP
Rohto Pharmaceutical Co Ltd
TSE:4527
Average P/E: 28.2
15.5
6%
2.6
FR
L'Oreal SA
PAR:OR
31.9
13%
2.5
UK
Unilever PLC
LSE:ULVR
11.7
-6%
N/A
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
35.2
N/A N/A
UK
HALEON PLC
LSE:HLN
18.4
11%
1.7
US
Estee Lauder Companies Inc
NYSE:EL
Negative Multiple: -161.1 N/A N/A
DE
Beiersdorf AG
XETRA:BEI
16.5
6%
2.7
JP
Kao Corp
TSE:4452
22.1
10%
2.2
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
59.9
18%
3.3
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -4 624.4 N/A N/A
IN
Dabur India Ltd
NSE:DABUR
42.5
11%
3.9

Market Distribution

In line with most companies in Japan
Percentile
34th
Based on 3 849 companies
34th percentile
16.3
Low
0.1 — 14.9
Typical Range
14.9 — 35
High
35 —
Distribution Statistics
Japan
Min 0.1
30th Percentile 14.9
Median 22.4
70th Percentile 35
Max 736 044 589.7

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
556.8B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
2 162.98 JPY
Overvaluation 8%
Intrinsic Value
Price ¥2 357.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett